By David Bautz, PhD NASDAQ: FBLG Business Update Phase 1/2 Trial of CYWC628 Underway On June 3, 2026, FibroBiologics, Inc.

FibroBiologics Inc. FBLG on Wednesday announced that it has enrolled and dosed the first patients in its Phase 1/2 clinical ...

FibroBiologics is conducting a prospective, multicenter, randomized clinical trial evaluating the safety, tolerability, and efficacy of CYWC628 in treating refractory diabetic foot ulcers with up to ...

Please provide your email address to receive an email when new articles are posted on . A master cell bank has been completed for a product that will utilize fibroblasts to treat chronic wounds.

A new study reviews how cancer-associated fibroblasts (CAFs) influence lymph node metastasis. Researchers identified various CAF subsets that interact with the tumor microenvironment, promoting cancer ...

The research group of Prof. Sanjiv Luther at the Department of Immunobiology of the University of Lausanne has discovered that a fibroblast subtype is essential for coordinating certain immune cells ...

Helmholtz Munich researchers revealed a conserved differentiation process with clinical implications for injury repair, identifying a multipotent fibroblast progenitor in the fascia— the deepest ...

New research led by Unity Health Toronto that examines how fibroblast cells in the body are activated to cause fibrosis and organ scarring has been published in Nature Reviews Molecular Cell Biology.

FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures ...

We recently compiled a list of the 10 Popular Penny Stocks on Robinhood to Watch in 2026. FibroBiologics, Inc. (NASDAQ:FBLG) ...